Huang, G.
Aroner, S. A.
Bay, C. P.
Gilman, S. E.
Ghassabian, A.
Loucks, E. B.
Buka, S. L.
Handa, R. J.
Lasley, B. L.
Bhasin, S.
Goldstein, J. M.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K08 HL132122-02)
Arizona Biomedical Research Commission (ADHS14-00003606)
National Institute of Mental Health (R01MH074679)
National Institute on Aging (RC2AG036666, R01AG023397)
Article History
Received: 15 June 2020
Accepted: 2 August 2020
First Online: 10 August 2020
Compliance with ethical standards
:
: Shalender Bhasin (SB) has received research grant support from Abbvie Pharmaceuticals, Transition Therapeutics, and Metro International Biotechnology, LLC for investigator-initiated research unrelated to this study. SB has served as a consultant to AbbVie and Novartis. SB has a financial interest in Function Promoting Therapies, LLC, a company aiming to develop innovative solutions that enhance precision and accuracy in clinical decision-making and facilitate personalized therapeutic choices in reproductive health. SB’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr. Goldstein is on the scientific advisory board for and has equity in Cala Health. However, this study has no relationship to the work in Cala Health. The rest of the authors have no conflicts of interest to disclose.
: The study protocol was approved by the institutional review boards at Partners HealthCare system and Brown University.
: All participants provided written informed consent.